

3 December 2025

Life Science REIT plc
(the "Company" or "LABS")
Appointment of Non-Executive Director

The Board of LABS today announces the appointment of Robert Naylor as the Senior Independent Non-Executive Director of the Company with immediate effect. Robert will replace Richard Howell as Senior Independent Non-Executive Director, who will continue in his role as a Non-Executive Director and Chair of the Audit Committee.

Robert has 29 years' experience in capital markets, specialising in the investment companies' sector. Robert is currently lead fund manager at Achilles Investment Company Limited, Non-Executive Chair of Aquila European Renewables plc (a closed-ended investment company specialising in renewable energy infrastructure), Non-Executive Director of PRS REIT plc, (a FTSE 250 closed-ended real estate investment company, which is in the process of being sold), Non-Executive Director of NIOX Group PLC (a company dedicated to improving asthma diagnosis and management) and Non-Executive Director of Renalytix plc (a precision medicine diagnostics company).

Previously, Robert was Non-Executive Chair of Hipgnosis Songs Fund Limited (a FTSE 250 closed-ended royalty investment company) and Non-Executive Chair of Round Hill Music Royalty Fund Limited. Earlier in his career, Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996.

The following information is disclosed in accordance with UK Listing Rule 6.4.8 in connection with the appointment of Robert Naylor to the Board of the Company:

Current Directorship	Previous Directorships in the past five years
Aquila European Renewables plc	Intuitive Investments Group Plc
PRS REIT plc	Round Hill Music Royalty Fund Limited
NIOX Group Plc	Light Science Technologies Holdings plc
Renalytix plc	Hipgnosis Songs Fund Limited

In addition to the above, Achilles Investment Company Limited hold 13,000,000 ordinary shares in the Company.

There are no additional matters that would require disclosure under UKLR 6.4.8 in respect of Robert Naylor.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Life Science REIT plc

Claire Boyle, Chair

via Panmure Liberum

Panmure Liberum - Financial Adviser & Corporate Broker

+44 20 7886 2500

Tom Scrivens / Chris Clarke / Alex Collins / Ashwin Kohli

The Company's LEI is 213800RG7JNX7K8F7525.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAFLLLBELLXFBE